Gina Columbus

China's National Medical Products Administration has approved zanubrutinib (Brukinsa) for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who have received at least 1 prior therapy, as well as for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

Infigratinib was found to demonstrate clinical activity in patients with metastatic urothelial carcinoma, regardless of what line of therapy it was administered.

Darolutamide (Nubeqa) plus androgen deprivation therapy led to a 31% reduction in the risk of death compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer.​​

The combination of pembrolizumab and axitinib continued to demonstrate a clinically significant improvement in progression-free and overall survival compared with sunitinib in patients with previously untreated, advanced renal cell carcinoma.

Pembrolizumab in combination with several chemotherapy partners led to a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy alone as a first-line treatment for patients with locally recurrent, inoperable, or metastatic triple-negative breast cancer whose tumors expressed PD-L1.

Adjuvant treatment with osimertinib demonstrated an 83% reduction in the risk of disease recurrence or death in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer.

R. Lor Randall, MD, FACS, discusses the cautions medical oncologists should take for their patients with bone sarcomas who undergo limb preservation with osteointegration, and the importance of keeping orthopedic oncologists in the loop.

LSZ102 was found to be well tolerated and demonstrate clinical activity in combination with either ribociclib or alpelisib in patients with estrogen receptor–positive breast cancer who have progressed on endocrine therapy.

The UK's National Institute for Health and Care Excellence has recommended the combination of atezolizumab and nab-paclitaxel as a treatment for patients with unresectable, locally advanced, or metastatic triple-negative breast cancer whose tumors express PD-L1 at a level of 1% or more and have not had prior chemotherapy for metastatic disease.

The combination of entinostat and exemestane did not show a statistically significant improvement in overall survival compared with exemestane alone in patients with advanced hormone receptor—positive, HER2-negative breast cancer who have progressed on a nonsteroidal aromatase inhibitor, missing the primary endpoint of the phase 3 E2112 trial.

The European Medicines Agency has validated a Marketing Authorization for the combination of tafasitamab and lenalidomide, followed by single-agent lenalidomide, for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma, including DLBCL arising from low-grade lymphoma, who are ineligible for autologous stem cell transplant.

The FDA has granted an orphan drug designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

We spoke with leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their specialties.

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.

Strategies with PARP inhibitors in ovarian cancer should focus on combination strategies to more effectively treat a heterogeneous patient population.

The combination of the RAF-MEK inhibitor VS-6766 (CH5126766) and the FAK inhibitor defactinib (VS-6063) elicited early signals of clinical activity in a group of patients with KRAS-mutant advanced cancers.

A minimally invasive blood test has been found to be feasible to safely detect several types of cancers in patients without a history of malignancies, enabling treatment with curative intent in a subset of individuals.

Adoptive cell transfer with tumor-infiltrating lymphocytes was found to be feasible, have a manageable toxicity profile, and expanded in 95% of patients with metastatic non–small cell lung cancer who had disease progression on nivolumab (Opdivo).

The addition of durvalumab (Imfinzi) and olaparib (Lynparza) to neoadjuvant paclitaxel was found to improve pathologic complete response rates compared with paclitaxel alone in patients with high-risk, HER2-negative stage II/III breast cancer.

The FDA has approved an expanded indication of ibrutinib for use in combination with rituximab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Toni K. Choueiri, MD, shares updates regarding the COVID-19 and Cancer Consortium and other changes he has experienced in clinical practice due to the ongoing COVID-19 pandemic.

The FDA has approved pemigatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements, as detected by an FDA-approved test.

The combination of olaparib and bevacizumab was found to improve progression-free survival outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the timing of surgery or residual disease status after surgery.

The combination of niraparib and bevacizumab as a frontline maintenance therapy was found to have impressive clinical activity in patients with advanced ovarian cancer who had a complete or partial response to frontline platinum-based chemotherapy plus bevacizumab.

Frontline maintenance treatment with Vigil immunotherapy demonstrated an improvement in relapse-free survival compared with placebo in patients with stage III/IV ovarian cancer, especially in those with BRCA1/2 wild-type disease.

The etiology and overall management of patients with early-onset colorectal cancer needs to be better understood and personalized, respectively, explained Andrea Cercek, MD, in a presentation during the 5th Annual School of Gastrointestinal Oncology™.

The FDA has approved durvalumab for the first-line treatment of adult patients with extensive-stage small cell lung cancer for use in combination with standard-of-care chemotherapy, which includes etoposide plus either carboplatin or cisplatin.

Brian I. Rini, MD, highlights the Uromigos podcast efforts to educate other oncologists on how COVID-19 will shift their practice, as well as adapting to changing procedures in clinic to continue delivering optimal care for patients with cancer during the pandemic.

Toni K. Choueiri, MD, highlights the changes he has observed in clinical practice amidst the COVID-19 pandemic and the unified approach being taken at Dana-Farber Cancer Institute.

Jeremy L. Warner, MD, MS, discusses the goals of the COVID-19 and Cancer Consortium Registry, what other data need to be extrapolated with COVID-19, and how the virus could impact patients with cancer.